Search
Novartis AG
NVSAdd to Watchlist
147.080USD
-3.790-2.51%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
282.22BMarket Cap
20.93P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Novartis AG is 6.20, ranking 131 out of 157 in the Pharmaceuticals industry. The average price target is 118.00, with a high of 147.42 and a low of 102.36.
Analyst Rating
Based on
10
analysts
Hold
Current Rating
143.654
Target Price
-2.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Novartis AG
NVS
10
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Novartis AG's expected revenue for the next quarter?
Novartis AG's expected revenue is 14.29B.
What is Novartis AG's price target?
Analysts forecast that Novartis AG's price target is USD 118.00, with the highest forecast at USD 147.42 and the lowest forecast at USD 102.36.
How have Novartis AGNVS's recent earnings per share performed?
The market expectation was USD 1.65, while Novartis AGNVS's earnings per share (EPS) for the previous quarter was USD 1.26. EPS for the next quarter is expected at USD 2.13.
What is the analyst rating for Novartis AG?
Based on the ratings of Novartis AG's stock from 10 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.
